ASX Announcement 20 October 2026 Microba secures $2.025 million placement and increases cost reduction programme Microba Life Sciences Limited (ASX: MAP) (Microba or the Company) announces that it has received firm commitments to raise $2.025 million (before costs) through a two-tranche placement...
Microba secures $2m placement and increases cost reductions
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Microba Life Sciences Limited has announced a placement to raise funds and implement cost reductions. The company secured commitments for a significant amount through a two-tranche placement to support its financial position and ongoing merger discussions. Additionally, Microba is reducing its annual operating costs and exploring the sale of its Invivo Supplements business. The filing also includes updates on leadership changes and trading performance for the first quarter of the fiscal year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Microba Life Sciences Limited on 6ix
Story so far
Earlier from Microba Life Sciences
- Date of AGM and closing date for Director Nominations
- Notification of cessation of securities - MAP
- Microba launches GI Navigator in Australia and the UK
- Change in substantial holding
- Appointment of Interim Chief Executive Officer
Later from Microba Life Sciences
- Q1 FY27 Quarterly Activities Report & Appendix 4C
- Proposed issue of securities - MAP
- Update on Commercial Terms for Proposed Merger with MAP
- Final Director's Interest Notice - Gene Tyson
- Final Director's Interest Notice - Ian Frazer
Follow Microba Life Sciences into a list and get an email when it puts out news.
Follow Microba Life Sciences